Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

US House Passes Legislation to Enable Venture Backed Small Business to Qualify

Related Content

Alexion and Samsung Settle Eculizumab BPCIA Case

Life Sciences Licensing and M&A Update: Catching Up on Recent Decisions Affecting Commercially Reasonable Efforts Definitions and Post-Patent Expiration Royalty Obligations

Antitrust and Competition Life Sciences Quarterly Update Q2 2024

The Centers for Medicare & Medicaid Services Announces Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation

PTAB Institutes Sarepta’s IPR

Antitrust and Competition Life Sciences Quarterly Update Q2 2024

Update on Recent International Biosimilar Approvals

Regeneron Files BPCIA Complaint Against Sandoz Regarding Aflibercept Biosimilar

Clients Name Goodwin an Intimidating Opponent in BTI Consulting’s Most Feared Law Firms in Litigation List

Goodwin Represents Underwriters On PACS Group’s Completed Upsized $690 Million Public Offering

Goodwin Named Venture Capital Firm of the Year, Hatch-Waxman Litigation Firm of the Year and Life Cycle Firm of the Year at the 2024 LMG Life Sciences Americas Awards

Goodwin Advises Arsenal Biosciences on $325 million Series C Funding Round

Goodwin Advises Collegium Pharmaceutical with Pharmakon Financing for Acquisition of Ironshore Therapeutics

Goodwin Advises eGenesis on $191 million Series D Funding Round

Hepta Medical Raises €5.7 Million in Series A Financing

Haventure Participates in the Fundraising and Creation of Kyniska Robotics

Life Sciences

Technology